Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05933395 · ClinicalTrials.gov registry record · Phase 2
Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor
A Phase 2 study of Advanced Breast Cancer, sponsored by Dartmouth-Hitchcock Medical Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 135
- Enrollment target
- 1
- Study location
NCT05933395 is a Phase 2 study of Advanced Breast Cancer that is actively recruiting participants, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 135 participants, below the 460-participant average among 28 other Advanced Breast Cancer trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05933395, a Phase 2 study of Advanced Breast Cancer, is actively recruiting participants, sponsored by Dartmouth-Hitchcock Medical Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 135 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to learn if certain drug combinations are effective treatments for patients with advanced ER+/HER2- who have previously been treated with palbociclib, ribociclib, or abemaciclib.
Conditions Studied
Interventions
- DRUG Neratinib
- DRUG Everolimus
- DRUG Fulvestrant
- DRUG Abemaciclib
- DRUG Alpelisib
Study Locations (1)
New Hampshire
- Dartmouth Hitchcock Medical Center - Lebanon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 135 participants |
| Start Date | 2024-09-23 |
| Est. Completion | 2031-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05933395
The ClinicalTrials.gov registry entry for NCT05933395 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 135 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 460-participant average among 28 other Advanced Breast Cancer trials with a reported enrollment target (71% lower). The listed sponsor is Dartmouth-Hitchcock Medical Center, which has 427 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which Neratinib is the first listed.
NCT05933395 reports 1 study location spanning 1 distinct geographic area - top geographies include New Hampshire.
Frequently Asked Questions
What is clinical trial NCT05933395 about?
NCT05933395 is a clinical study titled "Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor". The purpose of this study is to learn if certain drug combinations are effective treatments for patients with advanced ER+/HER2- who have previously been treated with palbociclib, ribociclib, or abemaciclib.
What is the current status of trial NCT05933395?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 135 participants. The study started on 2024-09-23. Estimated completion is 2031-10.
What conditions does trial NCT05933395 study?
This clinical trial studies the following conditions: Advanced Breast Cancer.
What interventions are being tested in trial NCT05933395?
The interventions under investigation include: Neratinib (DRUG), Everolimus (DRUG), Fulvestrant (DRUG), Abemaciclib (DRUG), Alpelisib (DRUG).
Who is sponsoring clinical trial NCT05933395?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05933395 being conducted?
This trial has 1 study location across New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
RECRUITING · Phase 2
-
Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib
ACTIVE NOT RECRUITING · Phase 2
-
RCT of CBD for Anxiety in Advanced Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor
COMPLETED · Phase 2
-
A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.